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We previously described that DNA vaccination with the gene encoding amastigote surface protein 2 (ASP-2)
protects approximately 65% of highly susceptible A/Sn mice against the lethal Trypanosoma cruzi infection.
Here, we explored the possibility that bacterial recombinant proteins of ASP-2 could be used to improve the
efficacy of vaccinations. Initially, we compared the protective efficacy of vaccination regimens using either a
plasmid DNA, a recombinant protein, or both sequentially (DNA priming and protein boosting). Survival after
the challenge was not statistically different among the three mouse groups and ranged from 53.5 to 75%. The
fact that immunization with a recombinant protein alone induced protective immunity revealed the possibility
that this strategy could be pursued for vaccination. We investigated this possibility by using six different
recombinant proteins representing distinct portions of ASP-2. The vaccination of mice with glutathione
S-transferase fusion proteins representing amino acids 261 to 500 or 261 to 380 of ASP-2 in the presence of the
adjuvants alum and CpG oligodeoxynucleotide 1826 provided remarkable immunity, consistently protecting
100% of the A/Sn mice. Immunity was completely reversed by the in vivo depletion of CD8 T cells, but not
CD4 T cells, and was associated with the presence of CD8 T cells specific for an epitope located between
amino acids 320 and 327 of ASP-2. We concluded that a relatively simple formulation consisting of a
recombinant protein with a selected portion of ASP-2, alum, and CpG oligodeoxynucleotide 1826 might be used
to cross-prime strong CD8-T-cell-dependent protective immunity against T. cruzi infection.
In spite of the significant reduction in transmission over the
past 20 years in countries such as Argentina, Brazil, Chile, and
Uruguay, Chagas’ disease (American trypanosomiasis) is still a
major problem for many Latin American countries. The dis-
ease afflicts more than 15 million individuals, with an annual
death toll of approximately 45,000 (reviewed in reference 18).
The efficacy of conventional chemotherapy with nifurtimox or
benznidazole is low and varies widely according to the infec-
tion status (acute or chronic) and the region of endemicity.
Because of the low efficacy of treatment, the chronic phase of
this infection usually persists for life. Approximately one-third
of infected persons progress slowly to the symptomatic forms
of the disease, characterized by cardiomyopathy and/or
megagastrointestinal syndromes. Asymptomatic, chronically
infected persons transmit the disease through blood transfu-
sions and tissue transplantation. The lack of efficient drug
treatment increases the importance of the development of new
strategies to prevent or reduce the disease.
A number of studies have been published over the past 10
years demonstrating that recombinant proteins or plasmid
DNA can elicit protective immunity against experimental
Trypanosoma cruzi infection (2, 3, 4, 5, 7, 8, 12, 16, 20, 21, 23,
24, 28, 31, 32, 33, 34; reviewed in references 17 and 22).
Vaccinated mice develop a strong cellular immune response
mediated by CD4 Th1 and CD8 Tc1, thus surviving other-
wise lethal acute infection. In addition to surviving acute in-
fection, chronic phase pathologies of vaccinated mice were
significantly reduced (4, 8, 28). Although in most studies, pro-
phylactic vaccinations were performed, a recent report showed
that therapeutic vaccination can also be effective in mice
chronically infected with certain T. cruzi strains (4). We con-
sider studies on vaccination against experimental Chagas’ dis-
ease important, as an efficacious vaccine may complement
other strategies such as vector control and chemotherapy for
prevention and treatment of the disease.
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Most experiments related to vaccination against T. cruzi
infection have used BALB/c or C57BL/6 mice. Although these
mice die when challenged with the infective trypomastigotes of
certain parasite strains, they are not as susceptible to infection
with T. cruzi as A/Sn mice. In order to study the mechanisms of
protective immunity required for vaccination, we have been
using A/Sn mice. This mouse strain is highly susceptible to
infection with different strains of T. cruzi, and 100% of the
animals die after a challenge with relatively small doses of the
parasite. Due to its high susceptibility, we believe that this
mouse strain provides an interesting model to study the immu-
nological mechanisms required to induce a high degree of
protective immunity against infection.
Using highly susceptible A/Sn mice, we have recently de-
scribed that vaccination with a plasmid expressing amastigote
surface protein 2 (ASP-2) generates specific CD4 Th1 and
CD8 Tc1 immune responses. Most importantly, immuniza-
tion with the asp-2 gene alone promotes the survival of ap-
proximately 65% of the A/Sn mice against a lethal Trypano-
soma cruzi infection (28). Protective immunity could be
improved if the animals were vaccinated simultaneously with
the genes of ASP-2 and trans-sialidase (28).
Based on the optimistic results obtained with the asp-2 gene,
we attempted to further improve protective immunity in this
mouse model of infection. To this end, the initial goal of the
present study was to compare the protective efficacy of vacci-
nation regimens using either plasmid DNA, recombinant pro-
tein, or both sequentially (DNA priming and protein boosting).
Our initial assumption was based on a number of reports
showing that a DNA priming/protein boosting strategy could
improve the protective efficacy in different vaccination models
(14, 19, 26, 27).
During the course of these experiments, we observed that
protective immunity was similar following immunization with
either a plasmid DNA or a recombinant protein adsorbed to
alum or when both types were combined (DNA priming/pro-
tein boosting). The fact that immunization with a recombinant
protein alone was partially protective was unexpected; how-
ever, it revealed the possibility that this strategy could be pur-
sued for experimental vaccination. Toward that goal, we used
several recombinant proteins representing distinct portions of
ASP-2. These proteins confirmed the protective potential of
recombinant antigens when used in a relatively simple adjuvant
formulation. Also, they identified a region containing highly
protective epitopes capable of providing protective immunity
to 100% of the vaccinated A/Sn mice.
MATERIALS AND METHODS
Mice and parasites. Female 5- to 8-week-old A/Sn mice were purchased from
the University of Sa˜o Paulo. Parasites of the Y strain of T. cruzi were used in this
study (25). Bloodstream trypomastigotes were obtained from mice infected 7
days earlier. The concentration of parasites was estimated and adjusted to 1,250
trypomastigotes per ml. Each mouse was inoculated intraperitoneally (i.p.) with
0.2 ml (250 trypomastigotes). Parasite development was monitored by counting
the number of bloodstream trypomastigotes in 5 l of fresh blood collected from
the tail vein (13).
Plasmid and recombinant proteins based on the sequence of the asp-2 gene.
The plasmid encoding the asp-2 gene, ASP-2 DNA, was created and purified as
previously described by Boscardin et al. (2). This plasmid contains the nucleo-
tides encoding the mouse immunoglobulin  chain signal peptide in frame with
the nucleotide sequence encoding amino acids (aa) 67 to 694 of ASP-2.
The nucleotide sequences corresponding to different portions of ASP-2 (clone
9) were obtained by PCR amplification using Platinum Taq High Fidelity DNA
polymerase (Invitrogen). Oligonucleotides containing the EcoRI and BamHI
restriction sites, purchased from Invitrogen, were used for amplification. The
amplified fragments were treated with the restriction enzymes EcoRI and
BamHI and ligated into the pGEX-3X vector (Amershan) treated with these
same enzymes. The recombinant plasmids were transformed into Escherichia coli
DH5. The recombinant proteins were expressed and purified as described
earlier (2). The purity of recombinant protein was determined by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). SDS molecular
weight markers (Sigma) were used as protein standards.
Immunization. A/Sn mice were immunized according to protocols described
earlier (3, 29). Each mouse received 3 doses of 100 g of plasmid DNA injected
intramuscularly at 0, 3, and 5 weeks. Immunization with recombinant His-65kDa
consisted of 3 i.p. doses of 25 g of protein adsorbed to alum (Alhydrogel 85
Superfos; Biosector, Vedbaek, Denmark) given at 0, 3, and 5 weeks. Efficient
coupling of recombinant His-65kDa to alum was obtained by mixing 2.5 l 2%
(wt/vol) Al2O3 per g of recombinant protein for 2 h. Our DNA priming/protein
boosting regimen consisted of two doses of 100 g of plasmid DNA injected at
0 and 3 weeks. A third dose was provided 2 weeks later and consisted of an i.p.
injection of 25 g of recombinant His-65kDa adsorbed to alum.
Immunization with the recombinant proteins His-65kDa, His-25kDa, glutathi-
one S-transferase (GST)-P1-P3, GST-P4-P7, GST-P4-P5, and GST-P6-P7 was
performed as described in the legend to Fig. 2. CpG oligodeoxynucleotide
(ODN) 1826 (TCCATGACGTTCCTGACGTT) was synthesized with a nucle-
ase-resistant phosphorothioate backbone (Coley Pharmaceutics, Wellesley,
MA).
One week after the last immunizing dose with plasmids and/or recombinant
proteins, the blood was collected from the tail and the sera were analyzed for the
presence of antibodies to His-65kDa. One week later, mice were challenged with
bloodstream trypomastigotes. Results are representative of two or more inde-
pendent experiments.
Immunological assays. Anti-His-65kDa antibodies were detected by enzyme-
linked immunosorbent assay as described earlier (2). Titers are reported as the
reciprocals of the highest serum dilution producing an average optical density at
492 nm greater than 0.1. The enzyme-linked immunospot assay (ELISPOT
assay) was performed essentially as described earlier (2).
Hemoculture and histopathological analysis. Aliquots of 0.1 ml of blood were
collected and cultured at 28°C for 1 month in 5 ml of axenic liver infusion
tryptose medium. Parasite growth was monitored microscopically every week.
Tissue specimens were collected from vaccinated and infected mice at the
indicated day after challenge and fixed in paraformaldehyde for further process-
ing. Paraffin-embedded tissue sections were stained with hematoxylin and eosin
stain and analyzed by optical microscopy. Slides from the heart and the quadri-
ceps muscle of each mouse were analyzed in a blind fashion by one of us
(C.R.F.M.). Areas of inflammatory infiltrates in the myocardium, pericardium,
and endocardium or in the striated muscle were analyzed and semiquantified.
In vivo depletion of CD4 and CD8 T cells. Ascites fluids containing GK1.5
and 53.6.7 monoclonal antibodies were produced in BALB/c nude mice, and the
concentration of rat immunoglobulin G (IgG) was estimated as described pre-
viously (15). At days 3 and 4 before challenge with trypomastigotes, mice im-
munized with GST-P4-P7 were treated i.p. with a dose of 1 mg per day of rat IgG,
anti-CD4, or anti-CD8. Seven days after challenge, each mouse received one
more dose of 1 mg of rat IgG, anti-CD4, or anti-CD8. The efficacy of depletion
of CD4 or CD8 spleen cells before challenge was commonly higher than 98 or
96%, respectively.
Peptide synthesis. The peptides KEGSKSGV (aa 94 through 101), AESL
FVYI (aa 121 through 128), HEHNLFGI (aa 130 through 137), YEIVAGYI (aa
140 through 147), AESWPSIV (aa 150 through 157), TEWETGQI (aa 320
through 327), and PETLGHEI (aa 650 through 658) were prepared with stan-
dard N[9-fluorenylmethyloxycarbonyl] on a PSSM8 multispecific peptide syn-
thesizer (Shimadzu, Kyoto, Japan) by solid-phase synthesis with a scale of 30
mol. Peptides were purified by high-pressure liquid chromatography in a Shi-
madzu system. Peptides were analyzed in a C18 Vydac column (10 by 250 mm,
5-m particle diameter). The peptides were obtained in a range of 80 to 90%
purity. Their identities were confirmed by using the Micro quantitative time of
flight mass spectrometer equipped with an electrospray ionization source (Mi-
cromass, United Kingdom).
Statistical analysis. The values of peak parasitemia of each individual mouse
were log transformed before being compared by one-way analysis of variance
followed by Tukey’s honestly significant difference (HSD) tests available at the
site http://faculty.vassar.edu/lowry/VassarStats.html. The log rank test was used
to compare the mouse survival rate after challenge with T. cruzi. Fisher’s exact
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test was used to compare the different proportions of mice that survived infec-
tion. The differences were considered significant when the P value was 0.05.
RESULTS
Initially, we compared the protective immune responses of
A/Sn mice immunized according to the group protocols
pcDNA3 (I), alum (II), ASP-2 DNA (III), Alum/His-65kDa
(IV), or ASP-2 DNA (V), followed by Alum/His-65kDa (DNA
priming/protein boosting). After a challenge with bloodstream
trypomastigotes of T. cruzi, we observed a significant reduction
in the peak parasitemia of animals from mouse groups III, IV,
and V compared to the control mice of groups I and II (P 
0.05 in all cases) (Table 1). The peak parasitemias of animals
from mouse groups III, IV, and V were not statistically differ-
ent (P  0.05).
We also recorded the mouse mortality among the different
mouse groups after the challenge with T. cruzi. Survival at day
60 was 75, 53.31, or 73.74% in mouse groups III, IV, or V,
respectively. Statistical comparisons were performed by the log
rank, chi-square, or Fisher exact probability tests. In all cases,
we failed to detect a significant difference among these three
mouse groups.
Based on the results that immunization with a recombinant
protein adsorbed to alum provided protective immunity, we
used six different recombinant proteins representing different
portions of ASP-2 for subsequent studies of vaccination. Fig-
ure 1A and 1B displays a schematic representation and the
SDS-PAGE analysis of the different recombinant proteins, re-
spectively.
Initially, A/Sn mice were immunized with the recombinant
proteins His-65kDa, GST-P1-P3, GST-P4-P7, and His-25kDa.
These recombinant proteins were adsorbed to alum and in-
jected i.p. in the presence of CpG ODN 1826. Control mice
were immunized with the adjuvants only (alum and CpG ODN
FIG. 1. Schematic representation and SDS-PAGE analysis of the recombinant proteins based on the ASP-2 antigen. (A) Schematic represen-
tation of the recombinant proteins. (B) SDS-PAGE of recombinant proteins stained with Coomassie blue. The amount of protein loaded was
approximately 1 g per lane.
TABLE 1. Trypomastigote-induced parasitemia and mortality in mice immunized with either ASP-2 DNA or recombinant protein
administered individually or sequentially (DNA priming/protein boosting)
Mouse
group no. Immunogen
a Peak parasitemia
(log  SD)b
No. of mice alive/total
no. challengedc % Protection
I pcDNA3 6.35  0.08 0/16 0
II Alum 6.53  0.05 0/8 0
III ASP-2 DNA 5.42  0.09 12/16 75.00
IV Alum/His-65kDa 5.62  0.32 8/15 53.31
V ASP-2 DNA plus alum/His-65kDa 5.55  0.23 11/15 73.74
a Groups of seven or eight mice were immunized at 0, 3, and 5 weeks with pcDNA3, ASP-2 DNA, alum, or the formulation alum/His-65kDa. A fifth group of mice
was injected with two doses of ASP-2 DNA at 0 and 3 weeks. A third immunizing dose was administered after 5 weeks and consisted of the formulation alum/His-65kDa.
b Two weeks after the last dose, mice were challenged i.p. with 250 bloodstream trypomastigotes. The values of peak parasitemia of mouse groups III, IV, and V were
lower than those for mouse groups I and II (P  0.05 in all cases). The peak parasitemias of groups III, IV, and V were not statistically different (P  0.05).
c The number of mice alive was recorded 60 days after challenge. Animals from groups III, IV, and V survived longer than mice from groups I and II (P  0.0001
in all cases by the log rank test). There was no significant statistical difference among groups III, IV, and V (P  0.05).
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1826). To determine whether the immunizations were per-
formed properly, after the third immunizing dose, the presence
of specific antibodies was determined by enzyme-linked immu-
nosorbent assay using the recombinant protein His-65kDa as
an antigen. The stronger antibody responses were detected in
animals immunized with recombinant protein His-65kDa or
His-25kDa. Antibody titers of mice immunized with GST-
P4-P7 were higher than the titers of mice immunized with
GST-P1-P3. Sera from control mice injected with adjuvant only
had no detectable specific antibodies to His-65kDa (data not
shown).
After challenge with bloodstream trypomastigotes in mice
immunized with His-65kDa or GST-P4-P7, we observed a sig-
nificant reduction in the peak parasitemia compared to ani-
mals immunized with adjuvant only, GST-P1-P3, or His-25kDa
(Fig. 2) (P  0.01 in all cases). No significant difference in
statistics was observed when we compared the peak para-
sitemia of mice immunized with His-65kDa or GST-P4-P7
(Fig. 2) (P  0.05). Also, no difference was found when we
compared the peak parasitemias of mice immunized with GST-
P1-P3 or His-25kDa or adjuvant alone (Fig. 2) (P  0.05).
Also important was the fact that immunization with His-
65kDa or GST-P4-P7 dramatically reduced mouse mortality
after a challenge. While 100% of the control mice injected with
adjuvant died before the 30th day after the challenge, 66.66%
or 100% of the mice immunized with His-65kDa or GST-P4-
P7, respectively, survived the challenge (Fig. 3). In contrast,
survival was limited in mice immunized with recombinant pro-
teins GST-P1-P3 or His-25kDa. In these cases, mouse survival
was 6.25% or 35.74%, respectively (Fig. 3).
Statistical analysis revealed significant differences in the sur-
vival of mice immunized with GST-P4-P7 compared to mice
immunized with other recombinant proteins or adjuvant only
(P  0.05 in all cases). Mice immunized with His-65kDa dis-
played a survival rate significantly higher than that for other
mouse groups, with the exception of the animals that received
GST-P4-P7 (P  0.05 in all cases). Mice immunized with His-
25kDa had a survival rate higher than that for the control
animals that received adjuvant only (P 0.05). In contrast, the
survival of mice injected with GST-P1-P3 or adjuvant only was
not statistically different (P  0.05).
The mice vaccinated with GST-P4-P7 that survived the chal-
lenge were rechallenged 56 days later. Seven of eight mice
survived this second challenge, while all negative control mice
immunized with adjuvant alone died (n  6). Parasitological
studies were performed on the surviving mice 77 days after the
second challenge. We found that 57.1% of the mice (four of
seven) harbored living parasites that could be isolated from
their blood. These results indicated that the majority of the
vaccinated mice were not able to completely eliminate the
parasites.
We also evaluated the presence of parasite nests and the
level of inflammatory response in their heart and striated mus-
cle. Histological analyses failed to detect the presence of par-
asite nests in the heart or striated muscle of mice vaccinated
with GST-P4-P7. No inflammatory lesions were found in the
striated muscle of vaccinated mice. In their heart tissue, either
no lesions or minimal lesions were found. We concluded that
most vaccinated A/Sn mice not only survived two challenges
with T. cruzi but also controlled the inflammatory reaction in
the skeletal and heart muscles (data not shown).
The recombinant protein GST-P4-P7 expresses aa 261 to
500 of ASP-2. In an attempt to further narrow the protective
epitopes present in this recombinant protein, we immunized
mice with two other proteins representing aa 261 to 380 (GST-
P4-P5) or aa 381 to 500 (GST-P6-P7) of ASP-2. After chal-
lenged with trypomastigotes, mice vaccinated with GST-P4-P7
or GST-P4-P5 displayed a peak parasitemia significantly lower
than that for animals injected with GST-P6-P7 or adjuvant
alone (Table 2) (P  0.01). No statistically significant differ-
ence was observed when we compared the peak parasitemia of
mice immunized with GST-P4-P7 or GST-P4-P5 (Table 2) (P
 0.05). Also, no difference was found when we compared the
peak parasitemia of mice immunized with GST-P6-P7 or ad-
juvant alone (Table 2) (P  0.05).
Statistical analysis revealed a significant difference in the
survival of mice immunized with GST-P4-P7 or GST-P4-P5
when compared to mice immunized with GST-P6-P7 or adju-
vant only (P  0.0001 in all cases). The survival of mice in-
jected with GST-P6-P7 or adjuvant only was not statistically
different (P  0.05) (Table 2). These results clearly indicated
that the protective epitopes present in GST-P4-P7 were lo-
cated at the aa 261 to 380 present in the recombinant protein
GST-P4-P5.
To determine the participation of either CD4, CD8, or
both types of T cells in the protective immunity observed after
immunization with the recombinant protein GST-P4-P7, we
treated vaccinated mice with anti-CD4 or anti-CD8 antibodies
prior to the challenge with T. cruzi. Treatment with monoclo-
nal antibody anti-CD8 dramatically increased mouse suscepti-
bility to infection compared to animals that received only rat
IgG. The peak parasitemia of mice treated with anti-CD8 was
significantly higher than that for vaccinated mice that received
rat IgG or anti-CD4 (P  0.05 in both cases) (Fig. 4A).
While 100% of the mice vaccinated with GST-P4-P7 and
treated with rat IgG survived the infection, 100% (10 of 10) of
anti-CD8-treated mice died (P 0.0001). In contrast, only 4 of
the 14 mice vaccinated with GST-P4-P7 and treated with anti-
CD4 died after the challenge (P  0.05) (Fig. 4B). We con-
cluded from these experiments that, in vivo, CD8 T cells were
critical to the efficient reduction of peak parasitemia and to
mouse survival after vaccination with the recombinant protein
GST-P4-P7.
Our results established that CD8 T cells provide the pro-
tective immunity observed after immunization with GST-P4-
P7. In order to determine whether we could detect specific
CD8 T cells in the spleens of mice immunized with the dif-
ferent recombinant proteins, we synthesized seven peptides
based on the predicted amino acid sequence of the asp-2 gene.
Peptides were selected by the presence of putative sites for
binding to A/Sn mouse major histocompatibility complex class
I gene product H-2Kk. Peptides with putative sites for binding
to H-2Dd were not present in the predicted amino acid se-
quence of the asp-2 gene (2).
The spleen cells of immunized mice were tested in the ELIS-
POT assay for their ability to secrete gamma interferon
(IFN-	) upon in vitro stimulation in the presence of the dif-
ferent peptides. During repeated experiments, we detected the
presence of peptide-specific IFN-	-secreting cells in the
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spleens of mice immunized with His-65kDa or GST-P4-P7
specific for the epitope represented by the synthetic peptide
TEWETGQI (Table 3). In contrast, in mice immunized with
GST-P1-P3 or His-25kDa, we were unable to detect the pres-
ence of specific IFN-	-secreting cells to the peptides tested
(Table 3). The epitope TEWETGQI is located between aa 320
and 327 of ASP-2. These amino acids are represented between
GST-P4-P7 and GST-P4-P5.
The phenotype of IFN-	-producing cells specific for the
peptide TEWETGQI was established using a selective in vivo
FIG. 2. Trypomastigote-induced parasitemia in A/Sn mice immunized with recombinant protein His-65kDa, GST-P1-P3, GST-P4-P7, or
His-25kDa. Groups of six mice were immunized at 0, 2, and 4 weeks with His-65kDa, GST-P1-P3, GST-P4-P7, His-25kDa, or adjuvant alone. Each
mouse received i.p. 25 g of recombinant protein adsorbed to alum in the presence of 10 g of CpG ODN 1826. Two weeks after the last dose
was administered, mice were challenged i.p. with 250 bloodstream trypomastigotes. The parasitemia for each individual mouse is represented. The
peak parasitemias of mice immunized with His-65kDa or GST-P4-P7 were lower than the parasitemias of animals immunized with adjuvant only,
GST-P1-P3, or His-25kDa (P  0.01 in all cases by Tukey’s HSD test). No significant difference was observed when we compared the peak
parasitemias of mice immunized with His-65kDa or GST-P4-P7 (P 0.05). Also, no difference was found when we compared the peak parasitemias
of mice immunized with GST-P1-P3 or His-25kDa or adjuvant alone (P  0.05).
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depletion approach. Mice immunized with GST-P4-P7 were
treated with either anti-CD4 or anti-CD8 or rat IgG. The
number of peptide-specific IFN-	-producing cells per 106
spleen cells of mice treated with rat IgG, anti-CD4, or anti-
CD8 was 170.0  16.9, 174.6  6.0, or 36.0  8.7, respectively.
Therefore, we concluded that the in vivo depletion of CD8
cells reduced the number of peptide-specific IFN-	-producing
cells by 79%. In contrast, depletion of CD4 cells had no impact
on the number of cells specific to the epitope TEWETGQI.
To determine whether there was a correlation between the
protective immunity observed after immunization with the re-
combinant proteins His-65kDa, GST-P4-P7, GST-P1-P3, or
His-25kDa and the immune response to the peptide TEWET
GQI, we evaluated the number of IFN-	-secreting cells in the
spleens of individual mice immunized with each recombinant
protein. The number of IFN-	-secreting cells specific to the
peptide TEWETGQI per 106 spleen cells in mice immunized
with GST-P4-P7 or His-65kDa were 147.11  28.87 and 41.66
 11.86, respectively (n  3, P  0.01, by Tukey’s HSD test).
In mice immunized with GST-P1-P3, His-25kDa, or adjuvant
only, we could not detect IFN-	-secreting cells specific for the
peptide TEWETGQI.
DISCUSSION
The aim of our study was to explore the possibility of using
bacterial recombinant proteins based on the ASP-2 antigen for
vaccination against experimental T. cruzi infection. Our initial
hypothesis was that a recombinant protein based on the ASP-2
antigen could be useful as a booster injection in mice previ-
ously immunized with DNA. We reasoned that this regimen
could enhance the protective immune response observed with
DNA vaccination alone. Contrary to this hypothesis, we found
that the survival of mice immunized with DNA alone or with a
DNA priming/protein boosting regimen was nearly identical
(75 or 73.74%, respectively).
Based on the partial protection that we observed, we de-
cided to pursue the question of whether recombinant proteins
of ASP-2 could be used to elicit protective immunity against a
T. cruzi infection. In the subsequent experiments, we added a
second adjuvant, CpG ODN 1826, to alum. We selected this
adjuvant based on previous studies showing that CpG ODN
1826 could improve Th1 immune response and protective im-
munity to a T. cruzi infection induced by a purified native
protein (6). At this point, the precise relevance of CpG ODN
1826 in our system is not clear. It is certainly not critical
because we can see significant protection in the absence of
CpG ODN 1826 after vaccination with His-65kDa or GST-
P4-P7 (Table 1 and data not shown, respectively). At the same
time, the presence of CpG ODN 1826 did help protective
efficacy. It is possible that the presence of CpG ODN 1826
increases the activation of specific CD8 T cells. This hypoth-
esis remains to be tested.
To map the protective determinants present within His-
FIG. 3. Trypomastigote-induced mortality in A/Sn mice immunized
with recombinant proteins His-65kDa, GST-P1-P3, GST-P4-P7, or
His-25kDa. The graph shows the Kaplan-Meier curves for the survival
of 14 to 16 mice per group. Statistical analysis revealed significant
differences in the survival of mice immunized with GST-P4-P7 com-
pared to that of mice immunized with other recombinant proteins or
adjuvant only (P  0.05 in all cases by the log rank test). Mice immu-
nized with His-65kDa displayed a survival rate significantly higher than
that for other mouse groups with the exception of the animals that
received GST-P4-P7 (P  0.05 in all cases). Mice immunized with
His-25kDa had a survival rate higher than that for the control animals
that received adjuvant only (P 0.05). In contrast, the survival of mice
injected with GST-P1-P3 or adjuvant only was not statistically different
(P  0.05).
TABLE 2. Trypomastigote-induced parasitemia and mortality in
A/Sn mice immunized with recombinant protein GST-P4-P7,
GST-P4-P5, or GST-P6-P7
Immunogena Peak parasitemia(log  SD)b
No. of mice
alive/total no.
challengedc
%
Protection
Adjuvant 6.06  0.16 0/6 0
GST-P4-P7 4.67  0.61 5/5 100
GST-P4-P5 4.96  0.34 6/6 100
GST-P6-P7 6.13  0.21 0/6 0
a Groups of five or six mice were immunized at 0, 2, and 4 weeks with
GST-P4-P7, GST-P4-P5, GST-P6-P7, or adjuvant alone as described in the
legend to Fig. 2. Two weeks after the last dose was given, mice were challenged
i.p. with 250 bloodstream trypomastigotes.
b The peak parasitemias in mice immunized with either GST-P4-P7 or GST-
P4-P5 were lower than those for animals immunized with GST-P6-P7 or adjuvant
alone (P  0.01 in all cases by Tukey’s HSD test). The peak parasitemias of mice
immunized with either GST-P4-P7 or GST-P4-P5 were not statistically different
(P  0.05).
c Mouse survival was recorded at day 60 after infection. Animals immunized
with GST-P4-P7 or GST-P4-P5 survived longer than mice injected with GST-
P6-P7 or adjuvant alone (P  0.0001 by the log rank test). There was no
significant statistical difference between the survival curves of mice vaccinated
with GST-P4-P7 or GST-P4-P5.
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65kDa, we used three proteins containing different domains of
ASP-2. Immunization with recombinant proteins GST-P1-P3
or His-25kDa representing the N- or the C-terminal domains
of ASP-2, respectively, provided limited protective immunity
compared to His-65kDa. In contrast, when we used a recom-
binant protein expressing aa 261 to 500 of ASP-2 (GST-P4-P7)
for vaccination, we obtained 100% protection against a lethal
challenge with T. cruzi trypomastigotes. Statistical analysis re-
vealed that the protective efficacy of the recombinant protein
GST-P4-P7 was higher than that of His-65kDa. The results
obtained with GST-P4-P7 not only confirmed the protective
potential of recombinant proteins based on the ASP-2 of T.
cruzi but also mapped highly protective epitope(s) to the cen-
tral domain of this molecule. Using a shorter recombinant
protein (GST-P4-P5), we were able to narrow this highly pro-
tective epitope(s) to the region between aa 261 and 380.
Whether smaller recombinant proteins, or even synthetic pep-
tides, can be used to vaccinate A/Sn mice remains to be eval-
uated.
Protective immunity obtained after immunization with GST-
P4-P7, alum, and CpG ODN 1826 was remarkable compared
to other protocols of immunization. This formulation provided
a high degree of protective immunity compared to ASP-2
DNA, His-65 kDa, or both in the same protocol of vaccination.
Until now, more than 50 mice immunized with this formulation
have been challenged. To date, all of these immunized mice
have survived T. cruzi challenge. Detailed studies on the lon-
gevity of protective immune responses induced with GST-
P4-P7 vaccination have yet to be performed. Nevertheless,
vaccinated A/Sn mice that survived the first challenge were
rechallenged 56 days later. Seven of eight mice survived infec-
tion, proving that this protective immunity is highly efficient.
Although protective immunity elicited by immunization with
recombinant protein GST-P4-P7 drastically reduced the peak
parasitemia and promoted mouse survival, we did not obtain
sterile immunity in most animals. In spite of the fact that sterile
immunity was not achieved, we found little or no inflammation
in the heart or striated muscle of mice challenged twice in the
course of 133 days. Our observations suggest that vaccination
controls acute-phase parasitemia, survival, and the develop-
ment of inflammatory responses in the heart and striated mus-
cle. Our results reinforce previously described observations
that immunity induced by T. cruzi ASP-2 encoding the DNA
vaccine gene drastically reduce the inflammatory responses in
the heart and skeletal muscle of A/Sn mice (28).
While vaccination with GST-P4-P7 protected 100% of the
mice against infection, immunization with His-65kDa or ASP-2
DNA never achieved this level of protective immunity. The
fact that immunization with GST-P4-P7 was more efficient
than the vaccination protocol using a larger recombinant pro-
tein correlated with the number of IFN-	-producing cells spe-
cific to the peptide TEWETGQI (Table 3). Therefore, it is
plausible to propose that the shorter GST-P4-P7 recombinant
protein can induce greater numbers of protective CD8 T cells
specific for the peptide TEWETGQI. The specific reason for
these results is currently unknown. It is possible that the pro-
tective epitope TEWETGQI may be better processed by anti-
gen-presenting cells after immunization with GST-P4-P7. Also,
the presence of GST may provide greater T-cell help to the
epitope TEWETGQI. Alternatively, we should evaluate
FIG. 4. Trypomastigote-induced parasitemia and mortality in mice
immunized with GST-P4-P7 and treated with anti-CD4 or anti-CD8
antibodies. Groups of five or six mice were immunized as described in
the legend to Fig. 2 with the recombinant protein GST-P4-P7 or
adjuvant alone. Mice immunized with the recombinant protein were
treated with rat IgG, anti-CD4, or anti-CD8 as described in Materials
and Methods. (A) The peak parasitemias in animals immunized with
GST-P4-P7 and treated with rat IgG or anti-CD4 were significantly
lower than the parasitemias of immunized animals treated with anti-
CD8 (P  0.01 in all cases by Tukey’s HSD test). The values of
parasitemia of mice immunized with GST-P4-P7 and treated with
anti-CD8 were not different from those of control mice injected with
adjuvant only (P  0.05). (B) The graph shows Kaplan-Meier curves
for the survival of 10 to 14 mice per group. Animals immunized with
GST-P4-P7 and treated with rat IgG or anti-CD4 survived longer than
mice treated with anti-CD8 (P  0.0001 by the log rank test). There
was no significant statistical difference between the survival curves of
mice vaccinated with the recombinant protein GST-P4-P7 and treated
with anti-CD8 or control animals injected with adjuvant alone (P 
0.05).
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whether His-65kDa contains an epitope(s) that activates reg-
ulatory T cells which can inhibit the CD8-T-cell immune
response to TEWETGQI.
Through depletion studies, we found that treatment with
anti-CD8, but not with anti-CD4 antibodies, completely re-
versed the protective immunity elicited by immunization with
GST-P4-P7. The fact that depletion of CD4 T cells had a
limited impact on protective immunity was not fully expected.
Our previous study has shown that when treated with anti-CD4
antibodies, mice vaccinated simultaneously with asp-2 and ts
genes were as susceptible to infection as anti-CD8-treated
mice (28). The results described here cannot be attributed only
to an inefficient elimination of CD4 T cells because immu-
nized mice were treated with the same antibodies and schedule
used in the previous report (28). Also, the extension of deple-
tion was monitored by fluorescence-activated cell sorter anal-
ysis before and after challenge. However, the most important
observation was the fact that mice treated with anti-CD8 were
as susceptible to infection as control mice injected with adju-
vant only. Therefore, it seems that in the absence CD8 T
cells, CD4 T cells were not able to provide a significant
degree of protective immunity. These results suggest a differ-
ent balance in these two T-cell populations after immunization
with DNA or the recombinant protein GST-P4-P7.
Previous studies have shown that formulations containing
distinct recombinant proteins could elicit protective immunity
in BALB/c or C57BL/6 mice against a lethal challenge with T.
cruzi (16, 20, 23, 32, 34). Depletions of CD4 or CD8 T cells
before challenge were not performed in animals vaccinated
with cruzipain or TC52 (20, 23). In the case of vaccination with
recombinant paraflagellar rod proteins, mice genetically defi-
cient in CD8 expression failed to develop protective immunity
against T. cruzi infection (34). Our results concur with these
latter results, and both studies confirm that CD8 T cells play
a critical role in protective immunity elicited by recombinant
proteins, as well as DNA vaccines (12, 28; reviewed in refer-
ences 17 and 22).
How are these protective CD8 T cells primed by the for-
mulation containing recombinant protein, alum, and CpG
ODN 1826? It is plausible to speculate that this formulation
uses the cross-priming route of antigen presentation (reviewed
in references 1 and 9). In fact, formulations containing CpG
ODN 1826 are described as capable of inducing specific CD8
T cells by the cross-priming route (10, 11; reviewed in refer-
ence 30). Whether this route of antigen presentation is oper-
ating in our case should be tested; this may provide an inter-
esting model to study the development of an anti-T. cruzi
vaccine.
In summary, our data on the protective immune response
elicited by recombinant proteins of the ASP-2 antigen created
a new model to study how recombinant proteins can be used to
elicit CD8-T-cell-mediated protective immune responses to
this intracellular pathogen. Also, we have confirmed and ex-
tended the results of several other studies that have described
the protective potential of this antigen (2, 5, 8, 28). Together,
they emphasize the importance of the immune response to
ASP-2 for the development of immunity to T. cruzi infection.
Studies on the immune response to ASP-2 may aid our under-
standing of the immunopathological mechanisms leading to
Chagas’ disease and the development of new strategies for the
prevention or treatment of the disease.
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